Mycophenolate mofetil as an alternate immunosuppressor for autoimmune lymphoproliferative syndrome

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 12, 2006, Pages 824-826

  Kossiva, Lydia ^a   Theodoridou, Maria ^a   Mostrou, Glykeria ^a   Vrachnou, Effie ^b   Le Deist, Francoise ^c   Rieux Laucat, Frederick ^c   Kanariou, Maria G ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Autoimmune cytopenia; Autoimmune lymphoproliferative syndrome; Corticosteroid; Mycophenolate mofetil

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; HUMAN; LABORATORY TEST; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; TREATMENT FAILURE;

ADRENAL CORTEX HORMONES; ANTIGENS, CD95; AUTOIMMUNE DISEASES; CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MUTATION; MYCOPHENOLIC ACID; SYNDROME; THROMBOCYTOPENIA; TIME FACTORS;

EID: 33845719057     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31802d7503     Document Type: Article

References (13)

1. Puck JM, Straus SE, LeDeist F, et al. Inherited disorders with autoimmunity and defective lymphocyte regulation. In: Ochs H, Smith CIE, Puck J, eds. Primary Immunodeficiency Diseases. A Molecular and Genetic Approach. New York: Oxford University Press; 1999:339-352.
2. Sneller MC, Wang J, Dale JK, et al. Clinical, immunologic, and genetic features of an autoimmune, lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89:1341-1348.
3. Bettinardi A, Brugnoni D, Quiròs-Roldan E, et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997;89:902-909.
4. Jackson CE, Puck JM. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Curr Opin Pediatr. 1999;11:521-527.
5. Rieux-Laucat F, Fischer A, Le Deist F. Cell-death signalling and human disease. Curr Opin Immunol. 2003;15:325-331.
6. Sabelko-Downes KA, Russell J. The role of Fas ligand in vivo as a cause and regulator of pathogenesis. Curr Opin Immunol. 2000;12:330-335.
7. Screaton G, Xu XN. T cell life and death signalling via TNF-receptor family members. Curr Opin Immunol. 2000;12:316-322.
8. Dianzani U, Bragardo M, Difranco D, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood. 1997;89:2871-2879.
9. Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70:353-357.
10. Howard J, Hoffbrand AV, Prentice HG, et al. Mycophenolate mofetil for the treatment of refractory autoimmune hæmolytic anemia and autoimmune thrombocytopenic purpura. Br J Haematol. 2002;117:712-715.
11. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
12. Infante AJ, Britton HA, Denapoli T, et al. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J Pediatr. 1998;133:629-633.
13. Rao VK, Dugan F, Dale JK, et al. Use of mycopfenolate for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005;129:534-538.